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Abstract
Background: Optic nerve hypoplasia (ONH) with/or without septo-optic dysplasia (SOD) is a known concomitant
of congenital growth hormone deficiency (CGHD).
Methods: Demographic and longitudinal data from KIGS, the Pfizer International Growth Database, were compared
between 395 subjects with ONH/SOD and CGHD and 158 controls with CGHD without midline pathology.
Results: ONH/SOD subjects had higher birth length/weight, and mid-parental height SDS. At GH start, height,
weight, and BMI SDS were higher in the ONH/SOD group. After 1 year of GH, both groups showed similar changes
in height SDS, while weight and BMI SDS remained higher in the ONH/SOD group. The initial height responses of
the two groups were similar to those predicted using the KIGS-derived prediction model for children with
idiopathic GHD. At near-adult height, ONH/SOD and controls had similar height, weight, and BMI SDS.
Conclusions: Compared to children with CGHD without midline defects, those with ONH/SOD presented with
greater height, weight, and BMI SDS. These differences persisted at 1 year of GH therapy, but appeared to be
overcome by long-term GH treatment.
Background
Optic nerve hypoplasia (ONH) is a congenital anomaly
often associated with hypopituitarism and brain malfor-
mations. It is relatively rare, with an incidence of 1 in
10,000 live births, and it equally affects boys and girls
[1]. The term septo-optic dysplasia (SOD), historically
and even today, is widely used interchangeably with that
of ONH. However, it is now known that absence of the
septum pellucidum per se does not confer increased risk
for growth hormone (GH) deficiency alone or as a com-
ponent of hypopituitarism in children with ONH [2,3].
In a study of 47 subjects [age (mean ± SD) 15.2 ± 10.6
months] with ONH followed until 59.0 ± 6.2 months of
age, Ahmad, et al reported a prevalence of endocrinopa-
thies of 71.7% (including 64.1% with GH-IGF-I axis
abnormalities); these were not associated with ONH
laterality, absence of septum pellucidum, or pituitary
abnormalities on neuro-imaging [2]. The only prior large,
long-term study looking at growth outcomes in children
described as having SOD treated with GH included 582
children enrolled in the National Cooperative Growth
Study (NCGS) (Genentech, S. San Francisco CA). Among
this cohort, 71 reached near-adult height (NAH) (mean
-1.57 ± 1.27 SD), representing a mean gain of 1.17 ± 1.49
SD after 6-7 years of GH treatment [4].
More recently, it has been suggested that obesity is a
frequent occurrence in children with ONH perhaps on a
hypothalamic basis [5,6]. In his cohort of 47 subjects
with ONH, Ahmad found that 44% had a body mass
index (BMI) > 85
th percentile at 5 years of age [2]. In
the large NCGS study, no weight or BMI data were
reported [4].
The purpose of the current analyses is to compare
presenting features and short- and long-term auxologi-
cal outcomes of GH treatment in children with ONH to
those of patients with congenital growth hormone defi-
ciency (CGHD) without non-pituitary midline defects or
ONH using data from KIGS (the Pfizer International
Growth Database).
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The KIGS database, established in 1987 and containing
data from over 70,000 patients in 51 different countries,
is an international registry developed with the main
objective of documenting the long-term outcomes and
safety of Somatonorm
® and Genotropin
® GH products
(Pfizer, Inc). The KIGS survey is performed in accor-
dance with the recommendations adopted by the 18
th
World Medical Assembly (held in Helsinki, Finland in
1964) and any subsequent revisions which exist to guide
physicians carrying out biomedical research involving
human individuals. Each subject and/or his/her legal
representative receive adequate information, has the
right to withdraw from the survey at any time, and con-
sents his/her participation, although, during the first
decade of its existence, this kind of registry or non-
interventional trial that KIGS represents did not require
informed consent from the subjects or legally acceptable
representatives in many countries.
To capture subject data from KIGS for the current
investigation, we included the diagnoses, ONH and/or
SOD, since the latter is still widely used to describe
patients with ONH whether or not the presence of the
septum pellucidum is documented. Hereafter, for simpli-
city, we refer to the study condition as ONH/SOD. As
of January 2009, there were 565 subjects identified as
having CGHD secondary to ONH/SOD and 244 control
subjects with CGHD unrelated to ONH/SOD and with-
out extra-pituitary midline pathology. A list of the diag-
nostic codes included in the non-ONH/SOD CGHD
group is included in Table 1. Subjects that were prepu-
bertal and had at least one year of longitudinal data
while receiving GH were included in the data analysis
(ONH/SOD group n = 395 and CGHD group n = 158).
Background demographic characteristics, birth mea-
surements, GH stimulation test results, and prevalence
of associated hypothalamic-pituitary deficiencies affect-
ing thyroid function, glucocorticoid production, and
water metabolism (diabetes insipidus) were collected
from KIGS. The prevalence of hypogonadism could only
be obtained in older subjects who reached NAH. The
subjects’ additional hormonal deficiencies were also
managed by their treating physicians. Auxological data
at the time of initiation of GH therapy and after one
year of treatment were also collected. Similar data of the
subsets of the two groups who attained NAH were com-
pared. NAH was defined by height velocity (< 2 cm/
year), bone age (≥ 14 years in females or ≥ 16 years in
males), and/or chronological age (> 15 years in females
and > 17 years in males).
Growth parameters are reported as standard deviation
scores (SDS) which were calculated based on standards
from Prader et al [7] and, for weight data, from Free-
man et al [8]. Birth weight and length SDS were calcu-
lated using the reference of Niklasson et al [9]. Bone
age readings were taken as reported by physicians and
were based on the methods of Greulich and Pyle [10] or
Tanner et al [11,12]. Data were not normally distributed
and, therefore, are presented as median and 10
th and
90
th percentiles. Wilcoxon rank-sum test was used to
detect differences between the two groups.
The heights of subjects in both groups were analyzed
using the previously published KIGS prediction model
for idiopathic GHD excluding GH maximum peak [13].
Differences between observed and predicted height velo-
cities are expressed in terms of Studentized residuals.
The residual is calculated as the observed height velocity
minus the predicted height velocity for each observation,
and the Studentized residual is the residual divided by
its standard error.
Results
Background characteristics were compared between the
two groups (Table 2). The birth length and weight SDS
were significantly greater in the ONH/SOD group com-
pared to the non-ONH/SOD CGHD group [birth length
SDS median (0.27); 10
th and 90
th percentiles (-1.3, 2.0)
vs. median (-0.62); 10
th and 90
th percentiles (-2.5, 1.2); p
< 0.001) and birth weight SDS (-0.31; -1.7, 1.1) vs.
(-0.58; -2.0, 1.0); p = 0.021)]. Mid-parental height SDS
was also significantly greater in the ONH/SOD group
(-0.23; -1.8, 1.3) compared to the non-ONH/SOD
CGHD group [(-1.04; -3.0, 0.5); p < 0.001]. Peak GH
levels on stimulation testing were similar between the
two groups. The ONH/SOD group had significantly
more subjects with other hypothalamic-pituitary hor-
mone deficiencies compared to the non-ONH/SOD
CGHD group (72.7% vs. 51.9%; p < 0.001), with involve-
ment of the thyroid and adrenal axes being the most
common.
At the start of GH therapy, both groups had similar
chronological ages and bone ages. However, the ONH/
SOD group had significantly greater height SDS [(-3.00;
-4.8, -0.9) vs. (-3.68; -6.7, -1.9); p < 0.001], weight SDS
[(-1.56; -4.2, 0.5) vs. (-2.56; -5.7, -0.6); p < 0.001], and
Table 1 KIGS diagnostic codes included in non-ONH/SOD
CGHD (cross-sectional numbers)
KIGS Diagnostic
Codes
n Description
2.1.1.1 23 GH gene-defect (Type 1A dominant or
recessive)
2.1.1.2 25 GH gene-defect
2.1.1.3 4 GHRH gene-defect
2.1.1.9 192 Other genetic cause of GHD
Total 244
GH, growth hormone; GHRH, growth hormone releasing hormone; GHD,
growth hormone deficiency
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Page 2 of 8BMI SDS [(0.22; -1.8, 2.1) vs. (-0.18; -2.1, 1.6); p =
0.001] (Table 2).
After one year on GH therapy, the two groups had
similar changes in height SDS (p = 0.066). The ONH/
SOD group continued to have a significantly higher
height SDS, weight SDS, and BMI SDS after one year
of GH therapy (all p < 0.001). However, height SDS
corrected for family height genetics was significantly
greater in the comparator group after the first year of
GH treatment (Figure 1). Use of the prediction model
for first-year growth response in children with idio-
pathic GHD showed that, although there was a slightly
greater than predicted response in the ONH/SOD
g r o u pv e r s u st h en o n - O N H / S O DC G H Dg r o u p ,t h e r e
was no difference in actual height response between
both groups, with Studentized residuals equivalent in
both groups (Figure 2).
NAH data were available for 59 subjects in the ONH/
SOD group and 23 subjects in the non-ONH/SOD
C G H Dg r o u p( T a b l e3 ) .T h et w og r o u p sh a ds i m i l a r
NAH at approximately -1 SDS (p = 0.430). The non-
ONH/SOD CGHD attained a NAH that was closer to
their mid-parental height (p < 0.05). The two groups
h a ds i m i l a rw e i g h tS D Sa n dB M IS D Sa tt i m eo fN A H
(Figure 3). At NAH, the two groups had the same pre-
valence of hypogonadism.
Discussion
Although over half of the patients with ONH/SOD will
develop an abnormality in their GH-IGF-I axis [2],
Table 2 Characteristics at background, GH start, and 1
st year on GH
ONH/SOD Non-ONH/SOD
N Median 10
th,9 0
th percentiles N Median 10
th,9 0
th percentiles P-value
Background
Gender, males 395 227 (57.5%) 158 101 (63.9%)
Birth Length SDS 206 0.27 -1.3, 2.0 104 -0.62 -2.5, 1.2 < 0.001
Birth Weight SDS 349 -0.31 -1.7, 1.1 133 -0.58 -2.0, 1.0 0.021
Mid-Parental Height SDS 324 -0.23 -1.8, 1.3 140 -1.04 -3.0, 0.5 < 0.001
Peak GH (μg/L) 307 2.60 0.8, 7.2 131 3.30 0.5, 10.8 0.053
Other Pituitary Hormone Deficiencies 395 287 (72.7%) 158 82 (51.9%) < 0.001
Hypothyroidism 395 250 (63.3%) 158 74 (46.8%) < 0.001
Glucocorticoid deficiency 395 206 (52.2%) 158 46 (29.1%) < 0.001
Diabetes insipidus 395 51 (12.9%) 158 6 (3.8%) < 0.001
At GH Start
Age (years) 395 3.99 0.9, 9.8 158 4.47 0.7, 10.7 0.498
Bone Age (years) 77 3.50 1.4, 8.7 41 4.00 1.2, 10.0 0.784
Height SDS 395 -3.00 -4.8, -0.9 158 -3.68 -6.7, -1.9 < 0.001
Height - Mid-Parental Height SDS 324 -2.74 -4.67, -0.62 140 -2.42 -4.94, -0.72 0.305
Height Velocity (cm/year) 147 5.46 2.35, 12.07 45 5.23 3.19, 9.76 0.904
Weight SDS 395 -1.56 -4.2, 0.5 158 -2.56 -5.7, -0.6 < 0.001
BMI SDS 395 0.22 -1.8, 2.1 158 -0.18 -2.1, 1.6 0.001
GH Dose (mg/kg/week) 395 0.24 0.16, 0.33 158 0.22 0.16, 0.39 0.395
1st yr on GH
Age (years) 395 5.01 1.87, 10.74 158 5.46 1.64, 11.75 0.500
Bone Age (years) 96 4.40 2.00, 9.00 53 4.17 2.00, 11.5 0.429
Height SDS 395 -1.95 -4.0, 0.0 158 -2.37 -4.7, -0.9 < 0.001
Δ Height SDS 395 1.02 0.0, 2.0 158 1.10 0.3, 2.7 0.066
Height - Mid-Parental Height SDS 324 -1.70 -3.78, 0.29 140 -1.29 -3.15, 0.23 0.010
Height Velocity (cm/year) 395 11.25 6.74, 16.18 158 10.54 6.98, 18.97 0.863
Weight SDS 393 -0.91 -3.3, 1.3 158 -1.81 -3.9, -0.0 < 0.001
BMI SDS 393 0.05 -1.8, 2.3 158 -0.43 -2.1, 1.2 < 0.001
GH Dose (mg/kg/week) 388 0.23 0.14, 0.33 156 0.21 0.13, 0.33 0.068
IGHD Prediction Model (Without GH Peak) at 1 year
Predicted Height Velocity 186 10.69 9.03, 12.51 73 9.99 8.28, 11.86 < 0.001
Actual Height Velocity (cm/year) 186 10.72 6.66, 14.37 73 9.49 7.16, 13.77 0.305
Studentized Residual 186 -0.11 -2.53, 1.98 73 -0.04 -1.61, 1.95 0.565
SDS, standard deviation score; GH, growth hormone
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Page 3 of 8little is known about their clinical presentations and
auxological responses to GH, especially in comparison
to those of similar patients with non-ONH/SOD
CGHD.
In our study, the birth length and weight were sig-
nificantly greater in the ONH/SOD group. It is
unclear whether these differences can be fully
explained by the increased mid-parental height seen in
  (a)                                (b)                          
    
  (c)                 (d)             
Figure 1 Comparison between groups. Comparison between groups with ONH/SOD vs. non-ONH/SOD CGHD of (a) height SDS, (b) height -
MPH SDS, (c) weight SDS, and (d) BMI SDS at start and after 1 year of GH therapy.
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Figure 2 Differences between observed and predicted height velocities. Differences between observed and predicted height velocities after
1 year of GH therapy in (a) ONH/SOD group and (b) non-ONH/SOD CGHD group were expressed in terms of Studentized residuals.
Table 3 Characteristics at Near-Adult Height
ONH/SOD Non-ONH/SOD
N Median 10
th,9 0
th
percentiles
N Median 10
th,9 0
th
percentiles
P-value
At GH Start
Gender, males 59 26 (44.1%) 23 10 (43.5%)
Age (years) 59 5.64 2.14, 11.76 23 5.12 2.09, 12.04 0.546
Height SDS 59 -3.77 -5.51, -1.96 23 -4.97 -7.73, -2.98 < 0.001
Height - Mid-Parental Height SDS 48 -3.41 -5.85, -1.78 22 -3.30 -5.81, -0.91 0.658
Weight SDS 59 -2.23 -4.44, -0.72 23 -3.49 -5.92, -0.80 0.013
BMI SDS 59 -0.13 -2.02, 1.86 23 0.09 -1.64, 1.56 0.955
GH Dose (mg/kg/week) 59 0.21 0.14, 0.31 23 0.21 0.14, 0.43 0.996
At NAH
Age (years) 59 17.73 15.5, 20.5 23 17.30 15.3, 19.4 0.369
Height SDS 59 -0.87 -2.8, 0.6 23 -1.37 -2.7, 0.2 0.430
Δ Height SDS (Latest minus Start) 59 2.75 1.1, 4.4 23 3.37 1.6, 6.1 0.025
Height - Mid-Parental Height SDS 48 -0.63 -2.35, 0.87 22 0.37 -1.59, 1.43 0.004
Weight SDS 59 -0.53 -2.6, 2.7 23 -0.22 -2.1, 1.9 0.988
BMI SDS 59 0.32 -1.90, 2.50 23 0.59 -0.90, 2.50 0.581
Mean Total GH Dose (mg/kg/week) 59 0.19 0.13, 0.28 23 0.19 0.14, 0.25 0.722
Years on GH Treatment 59 11.15 6.69, 16.37 23 11.51 6.71, 14.69 0.996
Hypogonadism 59 23 (39.0%) 23 9 (39.1%)
SDS, standard deviation score; GH, growth hormone
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ease-specific explanations. Some of this difference in
mid-parental height may be due to the parents of
those children with non-ONH/SOD CGHD also
having the same gene defect causing short stature. At
the time of diagnosis, the two groups had similar sti-
mulated peak GH levels suggesting a comparable
degree of GH deficiency.
 (a)                (b) 
  
 (c)                 (d) 
Figure 3 Comparison between groups with ONH/SOD vs. non-ONH/SOD CGHD. Comparison between groups with ONH/SOD vs. non-ONH/
SOD CGHD of (a) height SDS, (b) height - MPH SDS, (c) weight SDS, and (d) BMI SDS at near-adult height.
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cies seen in the ONH/SOD group compared to the non-
ONH/SOD CGHD group is not surprising given the
known association of ONH/SOD with hypopituitarism.
However, our study found, at the time of GH initiation,
for no obvious reason, a much higher prevalence of
associated hormone deficiencies in the ONH/SOD
g r o u pc o m p a r e dt ot h ed a t ar e p o r t e di nt h eN C G S
study (hypothyroidism: 63.2% vs 27%, glucocorticoid
deficiency: 52.2% vs 24%, and diabetes insipidus: 12.9%
vs 5%) [4]. In a smaller subset who reached NAH, 39%
of subjects in our cohort had hypogonadism while this
data was not reported in the NCGS study.
At the time of GH initiation, the ONH/SOD group
was significantly larger than the non-ONH/SOD CGHD
group in all measures (height, weight, and BMI). The
taller heights at diagnosis in the ONH/SOD group
might relate to the associated ophthalmological manifes-
tations of the condition leading to nystagmus and earlier
referral. This group’s greater genetic height potential
might also be contributory. As for the higher weight
and BMI, this may be associated with the intrinsic
hypothalamic dysfunction seen in some patients with
ONH/SOD causing hyperphagia.
The two groups responded similarly to one year of
GH therapy with a comparable increase in height and
similar to that predicted using the KIGS-derived predic-
tion model for first-year growth in GH-treated children
with idiopathic GHD. As a result, the ONH/SOD group
continued to have significantly greater height, along
with weight and BMI, than did the non-ONH/SOD
CGHD group. Although we recognize the small size of
the subsets from both groups that attained NAH and
the inherent uncertainty of being able to draw firm con-
clusions as a result, the available data suggest that the
two groups have similar height, weight, and BMI at
NAH. With height outcomes in both groups within 1
SD of the mean (corrected for their respective mid-par-
ental heights), this suggests that there is excellent adult
height potential in children with congenital GH defi-
ciency. Furthermore, these results suggest that long-
term GH therapy can possibly prevent, minimize, and/or
reverse the obesity that has been described in patients
with ONH/SOD. Additional randomized prospective
studies of GH therapy in patients with ONH/SOD are
needed to investigate the effects of GH therapy specifi-
cally on obesity and body composition.
In summary, children with ONH/SOD have different
presenting characteristics, but similar and normal final
height responses to GH therapy compared to children
with non-ONH/SOD CGHD. Because ONH/SOD is a
major risk factor for CGHD and these patients may not
be as short as those with non-ONH/SOD CGHD, it is
important for clinicians to have a high index of suspi-
cion and begin screening these patients for CGHD as
early as possible. GH therapy may have additional bene-
fits in this patient population as well with regard to
body composition thus making early diagnosis and treat-
ment even more important.
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